Glucosylceramides (buttermilk)
目录号 : GC48373Glucosylceramides are formed by the tethering of glucose to a ceramide by glucosylceramides synthase
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Glucosylceramides are formed by the tethering of glucose to a ceramide by glucosylceramides synthase.1 They are present in neuronal and non-neuronal mammalian tissues and are found at low quantities in a large number of plant species, where they comprise 5-30% of total lipids in the plant plasma membrane, and in fungi.1,2,3 Glucosylceramides levels decrease during cold acclimatization in plants and glucosylceramides in fungi are involved in the regulation of virulence and act as elicitors in plants, stimulating plant defense mechanisms.3,4 Glucosylceramides are precursors in the synthesis of lactosylceramides and gangliosides. Increased levels of glucosylceramides are associated with obesity-induced insulin resistance in mice and with neuronal deficits observed in neuronopathic Gaucher disease.1,5 This product is a mixture of glucosylceramides with variable ceramide chain lengths, extracted from bovine buttermilk. [Matreya, LLC. Catalog No. 1521]
1.Holland, W.L., and Summers, S.A.Sphingolipids, insulin resistance, and metabolic disease: New insights from in vivo manipulation of sphingolipid metabolismEndocr. Rev.29(4)381-402(2008) 2.Cahoon, E.B., and Lynch, D.V.Analysis of glucocerebrosides of rye (Secale cereale L. cv Puma) leaf and plasma membranePlant Physiol.95(1)56-68(1991) 3.Lynch, D.V., and Dunn, T.M.An introduction to plant sphingolipids and a review of recent advances in understanding their metabolism and functionNew Phytol.161(3)667-702(2004) 4.Rollin-Pinheiro, R., Bernardino, M.C., and Barreto-Bergter, E.Sphingolipids: Functional and biological aspects in mammals, plants, and fungiAnalysis of membrane lipids21-40(2020) 5.Dai, M., Liou, B., Swope, B., et al.Progression of behavioral and CNS deficits in a viable murine model of chronic neuronopathic Gaucher diseasePLoS One11(9)e0162367(2016)
| Cas No. | SDF | ||
| Canonical SMILES | O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC([R])=O)[C@@H]1O | ||
| 分子式 | C46H89NO8 (for docosanoyl) | 分子量 | 784.2 |
| 溶解度 | Chloroform:Methanol (2:1): Soluble | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2752 mL | 6.3759 mL | 12.7518 mL |
| 5 mM | 0.255 mL | 1.2752 mL | 2.5504 mL |
| 10 mM | 0.1275 mL | 0.6376 mL | 1.2752 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet